Which statement regarding Human papillomavirus (HPV) serotypes is true?

High-risk serotypes of Human papillomavirus (HPV), particularly types 16 and 18, are well-documented for their significant association with cervical precancers and cancers. Research indicates that these high-risk HPV types account for a substantial majority of cervical cancer cases globally, with estimates suggesting they are responsible for approximately 99% of cervical precancerous lesions (CIN 2 and CIN 3) as well as the vast majority of cervical cancer cases.

Understanding the distinction between high-risk and low-risk HPV serotypes is crucial. Low-risk types, such as 6 and 11, are typically associated with benign conditions like genital warts and do not contribute to the development of cervical cancer. In contrast, the high-risk serotypes are linked to malignant lesions, underscoring the importance of vaccination and screening strategies aimed at these specific types.

The other statements present inaccurate information regarding HPV. The assertion that HPV is a small RNA virus is incorrect, as HPV is categorized as a small DNA virus. Similarly, classifying type 16 as a low-risk serotype contradicts its established role as a high-risk type linked to over half of cervical cancer cases. Additionally, the claim that there are only 9 known serotypes overlooks the fact